Working... Menu

Study of Intraparenchymal Therapy as Adjunct Therapy in Patients With Recurrent, Resectable Glioblastoma Multiforme.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02433392
Recruitment Status : Terminated (The decision to terminate the trial was based on the slow rate of recruitment.)
First Posted : May 5, 2015
Last Update Posted : August 1, 2016
University of Birmingham
Information provided by (Responsible Party):
BTG International Inc.

Brief Summary:
The purpose of this trial is to determine the safety and feasibility of injecting irinotecan hydrochloride drug-eluting beads directly into the cavity remaining after a tumor is surgically removed in patients with a type of brain tumor (glioblastoma multiforme - also known as glioma) that has returned after prior therapy.

Condition or disease Intervention/treatment Phase
Glioma Procedure: CM-BC2 Phase 1

Detailed Description:
A challenge in the treatment of glioma is the delivery of treatment to the brain after systemic administration due to the blood brain barrier. To improve drug delivery to the brain to achieve very high local concentrations of the anti-neoplastic agent with low system toxicity, a local regional approach is proposed. CM-BC2, an irinotecan hydrochloride drug-eluting bead, is an investigational medicinal product intended for direction injection into the tumor resection margin. The objective of this trial is demonstration of safety and feasibility of this intraparenchymal injection of irinotecan hydrochloride drug-eluting beads in the treatment of recurrent Glioblastoma multiforme.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Study of Intraparenchymal Therapy With Irinotecan Hydrochloride Drug-eluting Beads (CM-BC2) as an Adjunct Therapy to Best Standard of Care in Patients With Recurrent, Surgically Resectable Glioblastoma Multiforme.
Study Start Date : December 2011
Actual Primary Completion Date : July 2015
Actual Study Completion Date : July 2015

Arm Intervention/treatment
Experimental: CM-BC2
Patients diagnosed with recurrent, surgically resectable glioblastoma multiforme will receive up to 75 mg irinotecan delivered by drug-eluting beads (CM-BC2).
Procedure: CM-BC2
CM-BC2 is a drug-eluting bead, a drug-device combination

Primary Outcome Measures :
  1. Safety measured by incidence of adverse events as assessed by CTCAE v4.0 [ Time Frame: 6 months ]
    safety of intraparenchymal injection of CM-BC2

Secondary Outcome Measures :
  1. Progression-free survival [ Time Frame: 6 months ]
    Progression-free Survival (PFS) at 6 months

  2. Systemic serum levels of irinotecan [ Time Frame: 6 months ]
    Serum levels of drug (irinotecan)

  3. Systemic serum levels of SN-38, irinotecan metabolite [ Time Frame: 6 months ]
    Serum levels of drug metabolite (SN-38)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. histologically confirmed diagnosis of Glioblastoma Multiforme (GBM) (World Health Organization grade IV)
  2. recurrent disease
  3. patient will be considered a good candidate for resection and will have estimated life expectancy of at least 12 weeks as estimated by the Principal Investigator or designee. The decision to opt for resection of the recurrence must be independent of study selection.
  4. Tumour characteristics:

    • Single unilateral and supratentorial lesion
    • On clinician's assessment, must be operable under normal considerations of risk vs. benefit for condition and prognosis
  5. patient will have received conventional treatment at the time of initial diagnosis, including surgery (biopsy or de-bulking), and/or radiotherapy, and/or chemotherapy
  6. male or female; no racial exclusions; at least 18 years of age
  7. Pregnancy must be excluded in female patients by beta- HCG (Human Chorionic Gonadotropin); all patients agree to use adequate contraception for study duration
  8. Karnofsky Performance Status of at least 60
  9. Patients must be able to understand consent and study instructions as well as follow prescribed instructions
  10. patient must have signed written informed consent prior to study participation

Exclusion Criteria:

  1. patient must not be enrolled in any other clinical trial for 30 days before or after participation in this trial
  2. history of allergic reactions attributed to compounds of similar chemical make-up or composition to CM-BC2, alginate or irinotecan; or has any other contraindications to irinotecan therapy
  3. open communication between the ventricle CSF (cerebrospinal fluid) and tumour resection cavity/site must be avoided. In the case of opening ventricles during surgery, the surgeon must decide whether effective closure is possible by obstructing the gap with Gelfoam/other appropriate materials
  4. Tumor surgery, other than stereotactic biopsy of the GBM, or other neurosurgery within 30 days prior to study entry
  5. Multiple GBM lesions
  6. Irinotecan chemotherapy within 30 days prior to study treatment
  7. radiotherapy or stereotactic (gamma knife) radiosurgery within 90 days prior to study entry
  8. loco-regional (intra-cranial) therapy for the treatment of GBM, including administration of biodegradable polymer wafers containing Carmustine and/or brachytherapy, in the 6 months prior to study entry
  9. Significant liver function impairment: aminotransferase (AST) or alanine transaminase (ALT) greater than 2.5 x the upper limit of normal (ULN), or total bilirubin greater than 2 x ULN
  10. significant renal impairment: creatinine greater than 2.0 mg/dL
  11. Coagulopathy Prothrombin time (PT) or partial thromboplastin time (APTT) of less than 1.5 x control, and/or platelet count of less than 100 x 10⁹/L
  12. Hb less than 8 g/dL and/or neutrophil count (ANC - Absolute Neutrophil Count) of less than 1 x 10⁹/L
  13. Any condition that, in the investigator's opinion, makes it in the patient's best interest not to participate in the study
  14. Pre-existing cerebral oedema that, in the surgeon's opinion, poses unacceptable risk of post-operative oedema. This decision may be at time of surgery.
  15. Presence of concurrent malignancy, except for adequately controlled limited basal cell carcinoma of the skin or carcinoma in situ of the cervix

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02433392

Layout table for location information
United Kingdom
Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust
Birmingham, United Kingdom, B15 2TH
Sponsors and Collaborators
BTG International Inc.
University of Birmingham
Layout table for investigator information
Principal Investigator: Garth Cruickshank, M.D. University Hospitals Birmingham NHS Foundation Trust

Layout table for additonal information
Responsible Party: BTG International Inc. Identifier: NCT02433392     History of Changes
Other Study ID Numbers: CA1021
First Posted: May 5, 2015    Key Record Dates
Last Update Posted: August 1, 2016
Last Verified: July 2016

Keywords provided by BTG International Inc.:
drug-eluting beads
irinotecan hydrochloride

Additional relevant MeSH terms:
Layout table for MeSH terms
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents